Table 1.
Position of two-drug regimens in HIV clinical guidelines.
| Naïve-to-ART Patients | ||||
| GeSIDA | EACS | DHHS | Observations | |
| DTG + 3TC | Recommended | Recommended | Recommended | HbS Ag-negative HIV VL < 500,000 copies/mL |
| RAL + bDRV | Not recommended | Alternative | Alternative | CD 4 count > 200 cells/mm3 HIV VL < 100,000 copies/mL |
| bDRV + 3TC | Not recommended | Not recommended | Alternative † | |
| Simplification in Virologically Suppressed Patients | ||||
| GeSIDA | EACS | DHHS | Observations | |
| DTG + RPV | Recommended | Recommended | Recommended | |
| DTG + 3TC | Recommended | Recommended | Recommended | |
| bPI + 3TC | Alternative | Recommended | Alternative ‡ | ‡ DRV is preferred over LPV and ATV |
| DTG + bDRV | Recommended | Alternative | Alternative | |
| bDRV + RPV | Not recommended | Alternative | Not recommended | |
ART: anti-retroviral treatment; GeSIDA: Grupo de estudio del SIDA; EACS: European AIDS Clinical Society; DHHS: Department of Health and Human Services; HbS Ag: hepatitis B surface antigen; HIV VL: human immunodeficiency virus viral load; DTG: dolutegravir; 3TC: lamivudine; RAL: raltegravir; bDRV: boosted-darunavir; RPV: rilpivirine; bPI: boosted-protease inhibitor; DRV: davunavir; LPV: lopinavir; ATV: atazanavir. † If chronic kidney disease is present, and only DRV/r.